Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Kissei Pharmaceutical Co. Ltd. et al v. Sandoz Inc.
Case Number:
1:13-cv-01092
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
April 12, 2017
Allergan, Kissei Settle With Sandoz In Prostate Drug Suit
Kissei Pharmaceutical and Allergan reached an agreement to dismiss all claims against Sandoz in litigation alleging the Novartis division infringed a patent for their enlarged-prostate medication Rapaflo by seeking approval for generic forms of the treatment, according to a Tuesday court filing in Delaware federal court.
-
August 21, 2013
Sandoz Wants Rapaflo Infringement Suit Trimmed
Sandoz Inc. on Monday asked a Delaware federal judge to trim a suit accusing its planned generic version of Actavis Inc.'s enlarged-prostate drug Rapaflo of infringing a patent covering the drug, saying the plaintiffs' claims were mostly speculative or barred by law.
-
June 19, 2013
Actavis Sues Sandoz, Hetero Over Generic Prostate Drug
Kissei Pharmaceutical Co. Ltd. and Actavis Inc. said Monday in virtually identical suits filed in Delaware federal court that Sandoz Inc. and Hetero Labs Ltd. infringed a patent for their enlarged-prostate drug by seeking approval for generic forms of the treatment.